ZYDIS® ODT Unlocks A Patient Preference For Rapid Onset In The Treatment Of Migraine

It has been reported that surveys of migraine patients have revealed a preference for oral medications with a rapid onset of action that leads to a resolution of their symptoms. Due to the random nature of migraine attacks, a dosage form that can be easily administered on the go without water can be beneficial for acute treatment of migraines.

Read the case study on how Biohaven partnered with Catalent to formulate an orally disintegrating tablet (ODT) to create a convenient dosage form with a shorter Tmax for the treatment of acute migraine.

Click here to view the Case Study